CORALLO, SALVATORE
CORALLO, SALVATORE
DIPARTIMENTO DI MEDICINA INTERNA E TERAPIA MEDICA
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium
2024-01-01 Lenti, M. V.; Ribaldone, D. G.; Borrelli de Andreis, F.; Vernero, M.; Barberio, B.; De Ruvo, M.; Savarino, E. V.; Kav, T.; Blesl, A.; Franzoi, M.; Gröchenig, H. P.; Pugliese, D.; Ianiro, G.; Porcari, S.; Cammarota, G.; Gasbarrini, A.; Spagnuolo, R.; Ellul, P.; Foteinogiannopoulou, K.; Koutroubakis, I.; Argyriou, K.; Cappello, M.; Jauregui-Amezaga, A.; Demarzo, M. G.; Silvestris, N.; Armuzzi, A.; Sottotetti, F.; Bertani, L.; Festa, S.; Eder, P.; Pedrazzoli, P.; Lasagna, A.; Vanoli, A.; Gambini, G.; Santacroce, G.; Rossi, C. M.; Delliponti, M.; Klersy, C.; Corazza, G. R.; Di Sabatino, A.; Mengoli, C.; Aronico, N.; Lepore, F.; Broglio, G.; Merli, S.; Natalello, G.; Alimenti, E.; Scalvini, D.; Muscarella, S.; Agustoni, F.; Pagani, A.; Chiellino, S.; Corallo, S.; Musella, V.; Cannizzaro, R.; Vecchi, M.; Caprioli, F.; Gabbiadini, R.; Dal Buono, A.; Premoli, A.; Locati, L. D.; Buda, A.; Contaldo, A.; Schiepatti, A.; Biagi, F.; Morano, D.; Cucè, M.; Kotsakis, A.; De Lisi, G.
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
2024-01-01 Niger, Monica; Nichetti, Federico; Fornaro, Lorenzo; Pircher, Chiara; Morano, Federica; Palermo, Federica; Rimassa, Lorenza; Pressiani, Tiziana; Berardi, Rossana; Gardini, Andrea Casadei; Sperti, Elisa; Salvatore, Lisa; Melisi, Davide; Bergamo, Francesca; Siena, Salvatore; Mosconi, Stefania; Longarini, Raffaella; Arcangeli, Giuseppina; Corallo, Salvatore; Delliponti, Laura; Tamberi, Stefano; Fea, Elena; Brandi, Giovanni; Rapposelli, Ilario Giovanni; Salati, Massimiliano; Baili, Paolo; Miceli, Rosalba; Ljevar, Silva; Cavallo, Ilaria; Sottotetti, Elisa; Martinetti, Antonia; Busset, Michele Droz Dit; Sposito, Carlo; Di Bartolomeo, Maria; Pietrantonio, Filippo; de Braud, Filippo; Mazzaferro, Vincenzo
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer A Subgroup Analysis of the TOSCA Randomized Clinical Trial
2020-01-01 Petrelli, F; Labianca, R; Zaniboni, A; Lonardi, S; Galli, F; Rulli, E; Rosati, G; Corallo, S; Ronzoni, M; Cardellino, Gg; Mattioli, R; Mambrini, A; Ciuffreda, L; Banzi, M; Pusceddu, V; Maiello, E; Zampino, M; Zagonel, V; Marchetti, P; Corsi, D; Rimassa, L; Cinieri, S; Sobrero, A
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial
2019-01-01 Di Bartolomeo, M; Niger, M; Morano, F; Corallo, S; Antista, M; Tamberi, S; Lonardi, S; Di Donato, S; Berardi, R; Scartozzi, M; Cardellino, Gg; Di Costanzo, F; Rimassa, L; Luporini, Ag; Longarini, R; Zaniboni, A; Bertolini, A; Tomasello, G; Pinotti, G; Scagliotti, G; Tortora, G; Bonetti, A; Spallanzani, A; Frassineti, Gl; Tassinari, D; Giuliani, F; Cinieri, S; Maiello, E; Verusio, C; Bracarda, S; Catalano, V; Basso, M; Ciuffreda, L; De Vita, F; Parra, Hs; Fornaro, L; Caporale, M; de Braud, F; Pietrantonio, F
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S
2021-01-01 Di Bartolomeo, M; Raimondi, A; Cecchi, F; Catenacci, Dvt; Schwartz, S; Sellappan, S; Tian, Y; Miceli, R; Pellegrinelli, A; Giommoni, E; Aitini, E; Spada, F; Rosati, G; Marchet, A; Pucci, F; Zaniboni, A; Tamberi, S; Pressiani, T; Sanna, G; Cantore, M; Mosconi, S; Bolzoni, P; Pinto, C; Landi, L; Parra, Hjs; Cavanna, L; Corallo, S; Martinetti, A; Hembrough, Ta; Pietrantonio, F
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
2020-01-01 Antoniotti, C; Borelli, B; Rossini, D; Pietrantonio, F; Morano, F; Salvatore, L; Lonardi, S; Marmorino, F; Tamberi, S; Corallo, S; Tortora, G; Bergamo, F; Brunella, D; Boccaccino, A; Grassi, E; Racca, P; Tamburini, E; Aprile, G; Moretto, R; Boni, L; Falcone, A; Cremolini, C
Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective
2022-01-01 Prisciandaro, M; Antista, M; Raimondi, A; Corti, F; Morano, F; Centonze, G; Sabella, G; Mangogna, A; Randon, G; Pagani, F; Prinzi, N; Niger, M; Corallo, S; di Caronno, Ec; Massafra, M; Di Bartolomeo, M; de Braud, F; Milione, M; Pusceddu, S
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study
2018-01-01 Pietrantonio, F; Fuca, G; Morano, F; Gloghini, A; Corso, S; Aprile, G; Perrone, F; De Vita, F; Tamborini, E; Tomasello, G; Gualeni, Av; Ongaro, E; Busico, A; Giommoni, E; Volpi, Cc; Laterza, Mm; Corallo, S; Prisciandaro, M; Antista, M; Pellegrinelli, A; Castagnoli, L; Pupa, Sm; Pruneri, G; de Braud, F; Giordano, S; Cremolini, C; Di Bartolomeo, M
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2020-01-01 Pietrantonio, F; Lobefaro, R; Antista, M; Lonardi, S; Raimondi, A; Morano, F; Mosconi, S; Rimassa, L; Murgioni, S; Sartore-Bianchi, A; Tomasello, G; Longarini, R; Farina, G; Petrelli, F; Gori, S; Randon, G; Corallo, S; Pagani, F; Guarini, V; Palermo, F; Martinetti, A; Macagno, M; Barault, L; Perrone, F; Tamborini, E; Milione, M; Di Nicolantonio, F; Di Maio, M; Fuca, G; Di Bartolomeo, M; de Braud, F
Chemotherapy-induced changes in plasma amino acids and lipid oxidation of resected patients with colorectal cancer: a background for future studies
2024-01-01 Aquilani, Roberto; Brugnatelli, Silvia; Maestri, Roberto; Iadarola, Paolo; Corallo, Salvatore; Pagani, Anna; Serra, Francesco; Bellini, Anna; Buonocore, Daniela; Dossena, Maurizia; Boschi, Federica; Verri, Manuela
Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality
2019-01-01 Antoniotti, C; Pietrantonio, F; Corallo, S; De Braud, F; Falcone, A; Cremolini, C
Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization
2019-01-01 Schirripa, M; Biason, P; Lonardi, S; Pella, N; Pino, Ms; Urbano, F; Antoniotti, C; Cremolini, C; Corallo, S; Pietrantonio, F; Gelsomino, F; Cascinu, S; Orlandi, A; Munari, G; Malapelle, U; Saggio, S; Fontanini, G; Rugge, M; Mescoli, C; Lazzi, S; Bonetti, Lr; Lanza, G; Dei Tos, Ap; De Maglio, G; Martini, M; Bergamo, F; Zagonel, V; Loupakis, F; Fassan, M
Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials
2020-01-01 Corallo, S; Fuca, G; Morano, F; Salati, M; Spallanzani, A; Gloghini, A; Volpi, Cc; Trupia, Dv; Lobefaro, R; Guarini, V; Milione, M; Cattaneo, L; Antista, M; Prisciandaro, M; Raimondi, A; Sposito, C; Mazzaferro, V; de Braud, F; Pietrantonio, F; Di Bartolomeo, M
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden
2020-01-01 Pietrantonio, F; Loupakis, F; Randon, G; Raimondi, A; Salati, M; Trapani, D; Pagani, F; Depetris, I; Maddalena, G; Morano, F; Corallo, S; Prisciandaro, M; Corti, F; Guarini, V; Bocconi, A; Marra, A; Belli, C; Spallanzani, A; Fassan, M; Lonardi, S; Curigliano, G; Fuca, G; Di Bartolomeo, M; de Braud, F
First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study
2018-01-01 Pietrantonio, F; Morano, F; Corallo, S; Raimondi, A; Loupakis, F; Cremolini, C; Smiroldo, V; Berenato, R; Sartore-Bianchi, A; Tampellini, M; Bustreo, S; Clavarezza, M; Murialdo, R; Zaniboni, A; Tomasello, G; Peverelli, G; Antoniotti, C; Procaccio, L; Cinieri, S; Antonuzzo, L; Di Bartolomeo, M; de Braud, F
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis
2021-01-01 Pietrantonio, F; Fuca, G; Rossini, D; Schmoll, Hj; Bendell, Jc; Morano, F; Antoniotti, C; Corallo, S; Borelli, B; Raimondi, A; Marmorino, F; Niger, M; Boccaccino, A; Masi, G; Lonardi, S; Boni, L; De Braud, F; Di Bartolomeo, M; Falcone, A; Cremolini, C
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study
2020-01-01 Raimondi, A; Di Maio, M; Morano, F; Corallo, S; Lonardi, S; Antoniotti, C; Rimassa, L; Sartore-Bianchi, A; Tampellini, M; Ritorto, G; Murialdo, R; Clavarezza, M; Zaniboni, A; Adamo, V; Tomasello, G; Petrelli, F; Antonuzzo, L; Giordano, M; Cinieri, S; Longarini, R; Bergamo, F; Niger, M; Antista, M; Peverelli, G; de Braud, F; Di Bartolomeo, M; Pietrantonio, F
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
2021-01-01 Raimondi, A; Fuca, G; Leone, Ag; Lonardi, S; Antoniotti, C; Smiroldo, V; Amatu, A; Tampellini, M; Ritorto, G; Murialdo, R; Clavarezza, M; Zaniboni, A; Berenato, R; Ratti, M; Corallo, S; Morano, F; Di Bartolomeo, M; Di Maio, M; Pietrantonio, F
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer
2021-01-01 Manca, P; Corallo, S; Randon, G; Lonardi, S; Cremolini, C; Rimassa, L; Bergamo, F; Antoniotti, C; Smiroldo, V; Zaniboni, A; Murialdo, R; Tampellini, M; Tomasello, G; Clavarezza, M; Racca, P; Antista, M; Raimondi, A; Prisciandaro, M; Pagani, F; Palermo, F; Greco, Fg; Vaiani, M; Di Bartolomeo, M; de Braud, F; Calareso, G; Morano, F; Pietrantonio, F
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component
2019-01-01 Moretto, R; Morano, F; Ongaro, E; Rossini, D; Pietrantonio, F; Casagrande, M; Antoniotti, C; Corallo, S; Marmorino, F; Cortiula, F; Nichetti, F; Borelli, B; Zucchelli, G; Boccaccino, A; Masi, G; de Braud, F; Falcone, A; Cremolini, C
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium | 1-gen-2024 | Lenti, M. V.; Ribaldone, D. G.; Borrelli de Andreis, F.; Vernero, M.; Barberio, B.; De Ruvo, M.; Savarino, E. V.; Kav, T.; Blesl, A.; Franzoi, M.; Gröchenig, H. P.; Pugliese, D.; Ianiro, G.; Porcari, S.; Cammarota, G.; Gasbarrini, A.; Spagnuolo, R.; Ellul, P.; Foteinogiannopoulou, K.; Koutroubakis, I.; Argyriou, K.; Cappello, M.; Jauregui-Amezaga, A.; Demarzo, M. G.; Silvestris, N.; Armuzzi, A.; Sottotetti, F.; Bertani, L.; Festa, S.; Eder, P.; Pedrazzoli, P.; Lasagna, A.; Vanoli, A.; Gambini, G.; Santacroce, G.; Rossi, C. M.; Delliponti, M.; Klersy, C.; Corazza, G. R.; Di Sabatino, A.; Mengoli, C.; Aronico, N.; Lepore, F.; Broglio, G.; Merli, S.; Natalello, G.; Alimenti, E.; Scalvini, D.; Muscarella, S.; Agustoni, F.; Pagani, A.; Chiellino, S.; Corallo, S.; Musella, V.; Cannizzaro, R.; Vecchi, M.; Caprioli, F.; Gabbiadini, R.; Dal Buono, A.; Premoli, A.; Locati, L. D.; Buda, A.; Contaldo, A.; Schiepatti, A.; Biagi, F.; Morano, D.; Cucè, M.; Kotsakis, A.; De Lisi, G. | |
| A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study | 1-gen-2024 | Niger, Monica; Nichetti, Federico; Fornaro, Lorenzo; Pircher, Chiara; Morano, Federica; Palermo, Federica; Rimassa, Lorenza; Pressiani, Tiziana; Berardi, Rossana; Gardini, Andrea Casadei; Sperti, Elisa; Salvatore, Lisa; Melisi, Davide; Bergamo, Francesca; Siena, Salvatore; Mosconi, Stefania; Longarini, Raffaella; Arcangeli, Giuseppina; Corallo, Salvatore; Delliponti, Laura; Tamberi, Stefano; Fea, Elena; Brandi, Giovanni; Rapposelli, Ilario Giovanni; Salati, Massimiliano; Baili, Paolo; Miceli, Rosalba; Ljevar, Silva; Cavallo, Ilaria; Sottotetti, Elisa; Martinetti, Antonia; Busset, Michele Droz Dit; Sposito, Carlo; Di Bartolomeo, Maria; Pietrantonio, Filippo; de Braud, Filippo; Mazzaferro, Vincenzo | |
| Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer A Subgroup Analysis of the TOSCA Randomized Clinical Trial | 1-gen-2020 | Petrelli, F; Labianca, R; Zaniboni, A; Lonardi, S; Galli, F; Rulli, E; Rosati, G; Corallo, S; Ronzoni, M; Cardellino, Gg; Mattioli, R; Mambrini, A; Ciuffreda, L; Banzi, M; Pusceddu, V; Maiello, E; Zampino, M; Zagonel, V; Marchetti, P; Corsi, D; Rimassa, L; Cinieri, S; Sobrero, A | |
| Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial | 1-gen-2019 | Di Bartolomeo, M; Niger, M; Morano, F; Corallo, S; Antista, M; Tamberi, S; Lonardi, S; Di Donato, S; Berardi, R; Scartozzi, M; Cardellino, Gg; Di Costanzo, F; Rimassa, L; Luporini, Ag; Longarini, R; Zaniboni, A; Bertolini, A; Tomasello, G; Pinotti, G; Scagliotti, G; Tortora, G; Bonetti, A; Spallanzani, A; Frassineti, Gl; Tassinari, D; Giuliani, F; Cinieri, S; Maiello, E; Verusio, C; Bracarda, S; Catalano, V; Basso, M; Ciuffreda, L; De Vita, F; Parra, Hs; Fornaro, L; Caporale, M; de Braud, F; Pietrantonio, F | |
| Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S | 1-gen-2021 | Di Bartolomeo, M; Raimondi, A; Cecchi, F; Catenacci, Dvt; Schwartz, S; Sellappan, S; Tian, Y; Miceli, R; Pellegrinelli, A; Giommoni, E; Aitini, E; Spada, F; Rosati, G; Marchet, A; Pucci, F; Zaniboni, A; Tamberi, S; Pressiani, T; Sanna, G; Cantore, M; Mosconi, S; Bolzoni, P; Pinto, C; Landi, L; Parra, Hjs; Cavanna, L; Corallo, S; Martinetti, A; Hembrough, Ta; Pietrantonio, F | |
| AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer | 1-gen-2020 | Antoniotti, C; Borelli, B; Rossini, D; Pietrantonio, F; Morano, F; Salvatore, L; Lonardi, S; Marmorino, F; Tamberi, S; Corallo, S; Tortora, G; Bergamo, F; Brunella, D; Boccaccino, A; Grassi, E; Racca, P; Tamburini, E; Aprile, G; Moretto, R; Boni, L; Falcone, A; Cremolini, C | |
| Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective | 1-gen-2022 | Prisciandaro, M; Antista, M; Raimondi, A; Corti, F; Morano, F; Centonze, G; Sabella, G; Mangogna, A; Randon, G; Pagani, F; Prinzi, N; Niger, M; Corallo, S; di Caronno, Ec; Massafra, M; Di Bartolomeo, M; de Braud, F; Milione, M; Pusceddu, S | |
| Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study | 1-gen-2018 | Pietrantonio, F; Fuca, G; Morano, F; Gloghini, A; Corso, S; Aprile, G; Perrone, F; De Vita, F; Tamborini, E; Tomasello, G; Gualeni, Av; Ongaro, E; Busico, A; Giommoni, E; Volpi, Cc; Laterza, Mm; Corallo, S; Prisciandaro, M; Antista, M; Pellegrinelli, A; Castagnoli, L; Pupa, Sm; Pruneri, G; de Braud, F; Giordano, S; Cremolini, C; Di Bartolomeo, M | |
| Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer | 1-gen-2020 | Pietrantonio, F; Lobefaro, R; Antista, M; Lonardi, S; Raimondi, A; Morano, F; Mosconi, S; Rimassa, L; Murgioni, S; Sartore-Bianchi, A; Tomasello, G; Longarini, R; Farina, G; Petrelli, F; Gori, S; Randon, G; Corallo, S; Pagani, F; Guarini, V; Palermo, F; Martinetti, A; Macagno, M; Barault, L; Perrone, F; Tamborini, E; Milione, M; Di Nicolantonio, F; Di Maio, M; Fuca, G; Di Bartolomeo, M; de Braud, F | |
| Chemotherapy-induced changes in plasma amino acids and lipid oxidation of resected patients with colorectal cancer: a background for future studies | 1-gen-2024 | Aquilani, Roberto; Brugnatelli, Silvia; Maestri, Roberto; Iadarola, Paolo; Corallo, Salvatore; Pagani, Anna; Serra, Francesco; Bellini, Anna; Buonocore, Daniela; Dossena, Maurizia; Boschi, Federica; Verri, Manuela | |
| Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality | 1-gen-2019 | Antoniotti, C; Pietrantonio, F; Corallo, S; De Braud, F; Falcone, A; Cremolini, C | |
| Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization | 1-gen-2019 | Schirripa, M; Biason, P; Lonardi, S; Pella, N; Pino, Ms; Urbano, F; Antoniotti, C; Cremolini, C; Corallo, S; Pietrantonio, F; Gelsomino, F; Cascinu, S; Orlandi, A; Munari, G; Malapelle, U; Saggio, S; Fontanini, G; Rugge, M; Mescoli, C; Lazzi, S; Bonetti, Lr; Lanza, G; Dei Tos, Ap; De Maglio, G; Martini, M; Bergamo, F; Zagonel, V; Loupakis, F; Fassan, M | |
| Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials | 1-gen-2020 | Corallo, S; Fuca, G; Morano, F; Salati, M; Spallanzani, A; Gloghini, A; Volpi, Cc; Trupia, Dv; Lobefaro, R; Guarini, V; Milione, M; Cattaneo, L; Antista, M; Prisciandaro, M; Raimondi, A; Sposito, C; Mazzaferro, V; de Braud, F; Pietrantonio, F; Di Bartolomeo, M | |
| Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden | 1-gen-2020 | Pietrantonio, F; Loupakis, F; Randon, G; Raimondi, A; Salati, M; Trapani, D; Pagani, F; Depetris, I; Maddalena, G; Morano, F; Corallo, S; Prisciandaro, M; Corti, F; Guarini, V; Bocconi, A; Marra, A; Belli, C; Spallanzani, A; Fassan, M; Lonardi, S; Curigliano, G; Fuca, G; Di Bartolomeo, M; de Braud, F | |
| First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study | 1-gen-2018 | Pietrantonio, F; Morano, F; Corallo, S; Raimondi, A; Loupakis, F; Cremolini, C; Smiroldo, V; Berenato, R; Sartore-Bianchi, A; Tampellini, M; Bustreo, S; Clavarezza, M; Murialdo, R; Zaniboni, A; Tomasello, G; Peverelli, G; Antoniotti, C; Procaccio, L; Cinieri, S; Antonuzzo, L; Di Bartolomeo, M; de Braud, F | |
| FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis | 1-gen-2021 | Pietrantonio, F; Fuca, G; Rossini, D; Schmoll, Hj; Bendell, Jc; Morano, F; Antoniotti, C; Corallo, S; Borelli, B; Raimondi, A; Marmorino, F; Niger, M; Boccaccino, A; Masi, G; Lonardi, S; Boni, L; De Braud, F; Di Bartolomeo, M; Falcone, A; Cremolini, C | |
| Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study | 1-gen-2020 | Raimondi, A; Di Maio, M; Morano, F; Corallo, S; Lonardi, S; Antoniotti, C; Rimassa, L; Sartore-Bianchi, A; Tampellini, M; Ritorto, G; Murialdo, R; Clavarezza, M; Zaniboni, A; Adamo, V; Tomasello, G; Petrelli, F; Antonuzzo, L; Giordano, M; Cinieri, S; Longarini, R; Bergamo, F; Niger, M; Antista, M; Peverelli, G; de Braud, F; Di Bartolomeo, M; Pietrantonio, F | |
| Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study | 1-gen-2021 | Raimondi, A; Fuca, G; Leone, Ag; Lonardi, S; Antoniotti, C; Smiroldo, V; Amatu, A; Tampellini, M; Ritorto, G; Murialdo, R; Clavarezza, M; Zaniboni, A; Berenato, R; Ratti, M; Corallo, S; Morano, F; Di Bartolomeo, M; Di Maio, M; Pietrantonio, F | |
| Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer | 1-gen-2021 | Manca, P; Corallo, S; Randon, G; Lonardi, S; Cremolini, C; Rimassa, L; Bergamo, F; Antoniotti, C; Smiroldo, V; Zaniboni, A; Murialdo, R; Tampellini, M; Tomasello, G; Clavarezza, M; Racca, P; Antista, M; Raimondi, A; Prisciandaro, M; Pagani, F; Palermo, F; Greco, Fg; Vaiani, M; Di Bartolomeo, M; de Braud, F; Calareso, G; Morano, F; Pietrantonio, F | |
| Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component | 1-gen-2019 | Moretto, R; Morano, F; Ongaro, E; Rossini, D; Pietrantonio, F; Casagrande, M; Antoniotti, C; Corallo, S; Marmorino, F; Cortiula, F; Nichetti, F; Borelli, B; Zucchelli, G; Boccaccino, A; Masi, G; de Braud, F; Falcone, A; Cremolini, C |